Prophylactic HPV vaccines.
The HPV L1 VLP vaccines are immensely important developments in public health and the benefits that they promise are immense, offering the opportunity to prevent, in the long term, 80% of cervical cancers, 60% of vulval cancers and 80% of anal cancers in women. In the short to medium term they will prevent at least 90% of genital warts and have a major impact on the incidence of high grade CIN, thus reducing the number of women who have to undergo LEEP and LLETZ. The health economic benefits will be substantial but the overwhelming benefit is the major improvement for human health and well-being. (
Stanley
Margaret
M
Department of Pathology, University of Cambridge, Cambridge, UK. mas@mole.bio.cam.ac.uk
D000818:Animals; D005260:Female; D005831:Genital Diseases, Female / Q000517:prevention & control; D006801:Humans; D008297:Male; D008403:Mass Screening / Q000379:methods; D027383:Papillomaviridae / Q000187:drug effects* / Q000276:immunology; D030361:Papillomavirus Infections / Q000453:epidemiology / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000494:pharmacology / Q000627:therapeutic use*; D018579:Patient Selection; D012307:Risk Factors
D053918:Papillomavirus Vaccines